Healius Limited (ASX:HLS)

Australia flag Australia · Delayed Price · Currency is AUD
0.8020
-0.0130 (-1.60%)
Jul 25, 2025, 11:39 AM AEST
-1.60%
Market Cap591.80M
Revenue (ttm)1.79B
Net Income (ttm)-22.80M
Shares Out726.13M
EPS (ttm)-0.03
PE Ration/a
Forward PEn/a
Dividend0.41 (51.63%)
Ex-Dividend DateMay 9, 2025
Volume524,964
Average Volume3,049,850
Open0.8000
Previous Close0.8150
Day's Range0.8000 - 0.8170
52-Week Range0.6950 - 1.8600
Beta0.40
RSI56.21
Earnings DateAug 21, 2025

About Healius

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics, QML Pathology, TML Pathology, Abbott Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medi... [Read more]

Sector Healthcare
Founded 1994
Employees 9,658
Stock Exchange Australian Securities Exchange
Ticker Symbol HLS
Full Company Profile

Financial Performance

In 2024, Healius's revenue was 1.75 billion, an increase of 2.30% compared to the previous year's 1.71 billion. Losses were -645.80 million, 75.6% more than in 2023.

Financial Statements

News

There is no news available yet.